Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · IEX Real-Time Price · USD
12.74
-0.13 (-1.01%)
Jun 13, 2024, 3:41 PM EDT - Market open

Company Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.

Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.

Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals logo
Country United States
IPO Date Nov 19, 2020
Industry Biotechnology
Sector Healthcare
Employees 75
CEO Dr. Sean P. Bohen M.D., Ph.D.

Contact Details

Address:
780 Brannan Street
San Francisco, California 94103
United States
Phone (415) 651-3316
Website olema.com

Stock Details

Ticker Symbol OLMA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001750284
CUSIP Number 68062P106
ISIN Number US68062P1066
Employer ID 30-0409740
SIC Code 2834

Key Executives

Name Position
Dr. Sean P. Bohen M.D., Ph.D. President, Chief Executive Officer and Director
Shane William Charles Kovacs M.B.A. Chief Operating and Financial Officer
Dr. Naseem Zojwalla M.D. Chief Medical Officer
Geoffrey Mogilner Vice President of Investor Relations and Communications
Julie Dexter Senior Vice President and Head of People
Dr. David C. Myles Ph.D. Chief Discovery and Non-Clinical Development Officer
Demiana Faltaos Ph.D., Pharm.D. Vice President and Head of Clinical Pharmacology
John B. Moriarty Jr., J.D. Corporate Secretary
Sasha Austin CPA Vice President of Finance and Controller

Latest SEC Filings

Date Type Title
Jun 6, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jun 6, 2024 144 Filing
Jun 6, 2024 144 Filing
Jun 4, 2024 144 Filing
Jun 3, 2024 144 Filing
May 31, 2024 144 Filing
May 15, 2024 8-K Current Report
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
May 6, 2024 144 Filing